FibroGen - FGEN Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" FGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FGEN, but not buy additional shares or sell existing shares.
View FGEN analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued twelve-month price targets for FibroGen's stock. Their FGEN share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests that the stock has a possible downside of 43.3%.
View analysts price targets for FGEN or view top-rated stocks among Wall Street analysts.

FibroGen's stock was trading at $14.10 at the beginning of the year. Since then, FGEN shares have increased by 0.1% and is now trading at $14.12.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our FGEN earnings forecast.

FibroGen, Inc. (NASDAQ:FGEN) issued its earnings results on Monday, August, 8th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.16. The biopharmaceutical company had revenue of $29.81 million for the quarter, compared to analyst estimates of $36.15 million. FibroGen had a negative net margin of 83.64% and a negative trailing twelve-month return on equity of 100.51%. The company's quarterly revenue was up 22.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.45) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.04%), Pictet Asset Management SA (0.33%), Swiss National Bank (0.22%), Walleye Capital LLC (0.20%), Pinnacle Associates Ltd. (0.18%) and JPMorgan Chase & Co. (0.15%). Insiders that own company stock include Christine Chung, Enrique A Conterno, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thane Wettig, Thomas B Neff and Thomas F Kearns Jr.
View institutional ownership trends.

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FGEN stock can currently be purchased for approximately $14.12.

FibroGen (NASDAQ:FGEN) has a market capitalization of $1.32 billion and generates $235.31 million in revenue each year. The biopharmaceutical company earns $-290,020,000.00 in net income (profit) each year or ($2.37) on an earnings per share basis.

The company employs 566 workers across the globe.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902.